

# UBS Equity Asian Consumption

## Manager Commentary

UBS Equity Funds > UBS Sector Funds

### Name of fund

UBS (Lux) Equity Fund - Asian Consumption (USD)

### ISIN

LU0763732723

### Share class

UBS (Lux) Equity Fund - Asian Consumption (USD) (CHF hedged) P-acc

### Reference Index

No representative reference index is available<sup>1</sup>

<sup>1</sup> For relative performance comparisons between fund and reference index please refer to the respective base currency share class of this fund.

Past performance is not a reliable indicator of future results.

### Performance in % (net of fees)<sup>1</sup>

in %	2015	2016	2017	2018	2019 YTD <sup>2</sup>	May 2019	5 years Ø p.a. 5 years	1.62
Fund (CHF)	-7.98	-3.70	45.76	-18.56	8.65	-7.27	8.37	

The performance shown does not take account of any commissions, entry or exit charges.

<sup>1</sup> These figures refer to the past. Source for all data and charts (if not indicated otherwise):

UBS Asset Management

<sup>2</sup> YTD: year-to-date (since beginning of the year)

### Risks

UBS Sector Funds invest in equities and may therefore be subject to high fluctuations in value. For this reason, an investment horizon of at least five years and corresponding risk tolerance and capacity are required. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

### For more information

UBS Fund Infoline: 0800 899 899

Internet: [www.ubs.com/funds](http://www.ubs.com/funds)

Contact your client advisor

### Portfolio management representatives

Manish Modi

Princy Singh

Vivien Ng

### Portfolio manager summary & review (May 2019)

Performance was negative in May, with China and Hong Kong detracting the most from returns.

Sector-wise, consumer discretionary, staples and communication services detracted the most.

The key stock contributors were HDFC Bank, Philippine Seven and DLF, while the main detractors were Alibaba, Tencent and LG Household & Health Care.

We exited WH Group, which has fared well since our purchase, as the recent escalation of trade war risks affect the company's fundamentals given the potential restrictions on US pork imports into China.

The markets did an about-turn in May, with the MSCI Asia ex Japan Consumer and Healthcare 10/40 index falling 9.7% in USD terms. Sentiment worsened as the US/China trade conflict re-escalated, with the US blacklisting Huawei and curbing the company's ability to do business with American firms, while for its part China raised the prospect of various retaliatory measures. Hong Kong and China fell the most in May, with Korea falling significantly too. Korea's healthcare and staples sectors fell the most. All three sectors in the index were down, with consumer staples declining the least and outperforming the customised index.

### Portfolio manager outlook (May 2019)

While some risks impacting Asia in 2018 have receded, the recent escalation of the trade conflict has clouded the near-term outlook for the continent. The Huawei ban effectively bars US companies from doing business with Huawei and could have wide-ranging first and second order effects well beyond this one company.

It is worth noting that the revenues of companies in the MSCI Asia ex Japan and China indices are overwhelmingly from domestic sources – over 60% for MSCI Asia ex Japan and over 90% for MSCI China – with only 7% and 2% respectively directly from the US. Additionally, intra-Asia trade continues to gain an increasing share of Asian exports. Furthermore, the predominant exposure in our portfolios is to domestic themes, especially stocks exposed to rising consumer affluence in Asian economies.

On average, Asian countries have high real rates, while fiscal balances have improved and inflation is in check. As a result there is scope for policy easing if required.

China has both the ability and willingness to partly offset the impact of the trade conflict via fiscal, monetary and regulatory measures, as it has done since Q4 2018. Elsewhere in the region, we see southeast Asia as a potential beneficiary of the trade conflict as companies gradually diversify their production away from China. India and Indonesia (barring uncertainties in relation to General Prabowo Subianto's challenge to the Indonesian election results) saw positive election outcomes which should provide reform continuity and revive private sector sentiment, with investment expected to pick up. We have reduced our positions in China by lowering our exposure to Chinese liquor businesses such as Kweichow

# UBS Equity Asian Consumption

Moutai and Wuliangye Yibin as well as hotpot condiments company Yihai, which have had a strong run in the year to date. We continue to focus on long-term themes such as the increasing share of discretionary spending and premiumisation, China's rebalancing into services and consumption and the underpenetration of credit across India. We are also watching for potential opportunities as stocks may get sold down beyond the extent warranted by fundamentals.

Please note that additional fees (e.g. entry or exit fees) may be charged. Please refer to your financial adviser for more details. Investors should read the Key Investor Information Document (KIID), Prospectus and any applicable local offering document prior to investing. For a definition of financial terms refer to the glossary available at [www.ubs.com/glossary](http://www.ubs.com/glossary).

**For marketing and information purposes by UBS.** UBS funds under Luxembourg law. Representative in Switzerland for UBS funds established under foreign law: UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. Paying agent: UBS Switzerland AG, Bahnhofstrasse 45, CH-8001 Zurich. Prospectuses, simplified prospectuses or Key investor information, the articles of association or the management regulations as well as annual and semi-annual reports of UBS funds are available free of charge from UBS AG, P.O. Box, CH-4002 Basel or from UBS Fund Management (Switzerland) AG, P.O. Box, CH-4002 Basel. The fund documentation is available free of charge in English and, where relevant, in one of the local language(s) where the fund is registered. Before investing in a product please read the latest prospectus carefully and thoroughly. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided by UBS without any guarantee or warranty and are for the recipient's personal use and information purposes only. This document may not be reproduced, redistributed or republished for any purpose without the written permission of UBS AG. Source for all data and charts (if not indicated otherwise): UBS Asset Management This document contains statements that constitute "forward-looking statements", including, but not limited to, statements relating to our future business development. While these forward-looking statements represent our judgments and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. © UBS 2019. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.